IONS vs PEN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IONS presents a significant disconnect between its market valuation and fundamental performance. While the Piotroski F-Score of 5/9 indicates stable financial health, the company is grappling with negative revenue growth (-10.30%) and a severe collapse in YoY EPS (-167.4%). Despite a massive 181% price surge over the last year, the valuation is extreme with a Price/Book of 25.10 and a Price/Sales of 13.16. Heavy insider selling by the CEO and CFO, combined with a bearish technical trend, suggests the current price is driven by speculative pipeline expectations rather than realized value.
Penumbra exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet characterized by low debt and high liquidity. While the company demonstrates impressive growth metrics, including 38.3% earnings growth and a PEG ratio of 0.74, the current price of $325.33 represents a massive premium over its Graham Number ($60.84) and Intrinsic Value ($133.34). The bullish growth trajectory is currently offset by bearish insider sentiment and a negative technical trend, suggesting the stock may be overextended in the short term.
Compare Another Pair
Related Comparisons
IONS vs PEN: Head-to-Head Comparison
This page compares Ionis Pharmaceuticals, Inc. (IONS) and Penumbra, Inc. (PEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.